w9gg3sjz | Knowledge4COVID-19

Property	Value
?:abstract	Objective: Galidesivir-BCX4430 is an antiviral broad spectrum drug with an adenosine nucleotide analogue Galidesivir behaves in vitro against numerous RNA viral pathogens, which include the filoviruses and develops irresistible contagious to humans, for example, MERS CoV and SARS-CoV In vivo, BCX4430 is agile after intramuscular, intraperitoneal administration, and on more, oral organization in an assortment of test contaminations Recent studies have stated that this drug is currently being examined for treatment of COVID 19 as previously it has been used in zika virus, Ebola and also Hepatitis C Methods: The study was to investigate the binding efficiency of selected currently COVID 19 treating drugs and visualized by Discovery Studio 4 1 Visualizer The target sites of drugs selected for the study were extracted from Protein Data Bank, and the ligands selected for the study are (R1-R7)Among the compounds treated with targets are screened in Autodock CompoundR5 shows greater binding efficacy Results: Compound R5 shows better antiviral activity and inhibition and active protease inhibitor and promotes to treat Sars cov 2 (COVID-19) © 2020, Advanced Scientific Research All rights reserved
is ?:annotates of	<https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0003451> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0023688> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0033607> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0035691> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0085150> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0318793> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C0597107> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C1175743> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C1335648> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C3698360> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C3890230> <https://research.tib.eu/covid-19/entity/w9gg3sjz_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Hemalatha%2C_C._N.%3B_Hemamalini%2C_B.%3B_Harikrishnan%2C_N.>
?:journal	International_Journal_of_Pharmaceutical_Research
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/w9gg3sjz_HAS_C0003451_TREATS_C5203670> <https://research.tib.eu/covid-19/entity/w9gg3sjz_HAS_C0033607_TREATS_C5203676> <https://research.tib.eu/covid-19/entity/w9gg3sjz_HAS_C1175743_COEXISTS_WITH_C0318793> <https://research.tib.eu/covid-19/entity/w9gg3sjz_HAS_C1870231_INTERACTS_WITH_C0013227> <https://research.tib.eu/covid-19/entity/w9gg3sjz_HAS_C3698360_COEXISTS_WITH_C0318793>
?:source	WHO
?:title	Reimposing of marketed drugs in treatment of COVID 19 by insilicomethods
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#826125
?:year	2020

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/w9gg3sjz>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/w9gg3sjz>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all